S&P 500   0.72 (+0.00%)
DOW   0.72 (+0.00%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+0.00%)
DOW   0.72 (+0.00%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+0.00%)
DOW   0.72 (+0.00%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+0.00%)
DOW   0.72 (+0.00%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
Log in

NASDAQ:CLCDCoLucid Pharmaceuticals Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$46.52
0.00 (0.00 %)
(As of 03/2/2017)
Add
Today's Range
$46.53
Now: $46.53
$46.53
50-Day Range N/A
52-Week Range
$5.26
Now: $46.53
$46.65
VolumeN/A
Average Volume708,479 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
CoLucid Pharmaceuticals, Inc. is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Lasmiditan, the Company's lead product candidate, is an oral tablet for the acute treatment of migraine in adults. Lasmiditan selectively targets 5-HT1F receptors expressed in the trigeminal pathway in the central nervous system (CNS). Lasmiditan is designed to penetrate the CNS and block the pathway that contributes to headache pain. It is developing IV lasmiditan for the acute treatment of headache pain associated with migraine in adults, to be used in emergency rooms and urgent care settings. The Company is conducting its Phase III randomized, double-blind, placebo-controlled clinical trial of lasmiditan.
Read More
CoLucid Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.66 out of 5 stars


Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:CLCD
CUSIPN/A
Phone+1-781-3652596

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive CLCD News and Ratings via Email

Sign-up to receive the latest news and ratings for CLCD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











CoLucid Pharmaceuticals (NASDAQ:CLCD) Frequently Asked Questions

How were CoLucid Pharmaceuticals' earnings last quarter?

CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) posted its quarterly earnings data on Wednesday, November, 9th. The biopharmaceutical company reported ($0.79) EPS for the quarter, meeting analysts' consensus estimates of ($0.79).
View CoLucid Pharmaceuticals' earnings history
.

Has CoLucid Pharmaceuticals been receiving favorable news coverage?

News articles about CLCD stock have been trending negative recently, according to InfoTrie Sentiment. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. CoLucid Pharmaceuticals earned a news impact score of -2.4 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term.
View the latest news about CoLucid Pharmaceuticals
.

What other stocks do shareholders of CoLucid Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CoLucid Pharmaceuticals investors own include Gilead Sciences (GILD), Kite Pharma (KITE), Dova Pharmaceuticals (DOVA), Opko Health (OPK), Novavax (NVAX), Square (SQ), Ariad Pharmaceuticals (ARIA), Bausch Health Companies (BHC), Biopharmx (BPMX) and Biostar Pharmaceuticals (BSPM).

When did CoLucid Pharmaceuticals IPO?

(CLCD) raised $55 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 5,500,000 shares at a price of $10.00 per share. Piper Jaffray and Stifel served as the underwriters for the IPO and William Blair was co-manager.

What is CoLucid Pharmaceuticals' stock symbol?

CoLucid Pharmaceuticals trades on the NASDAQ under the ticker symbol "CLCD."

What is CoLucid Pharmaceuticals' stock price today?

One share of CLCD stock can currently be purchased for approximately $46.53.

What is CoLucid Pharmaceuticals' official website?

The official website for CoLucid Pharmaceuticals is www.colucid.com.

How can I contact CoLucid Pharmaceuticals?

CoLucid Pharmaceuticals' mailing address is 222 3rd St, CAMBRIDGE, MA 02142-1102, United States. The biopharmaceutical company can be reached via phone at +1-781-3652596.

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.